News | April 01, 2022
Sumitomo Chemical to build new API and intermediates plant in Japan
The plant is scheduled to come on stream in September 2024
The plant is scheduled to come on stream in September 2024
The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
The registry will be conducted for approximately two and a half years and up to 200 subjects will be enrolled
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
Data to establish the safety profile and human dose of vaccine candidate
Milltrust Ventures will also assist Oncoshot with its expansion in Australia and India, where the latter has already established partnerships amongst apex cancer institutes
The facility will produce 150 million vaccine doses per year
The generic version of Sinequan, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis
Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and Delta
Subscribe To Our Newsletter & Stay Updated
